Adults 18 to 75, any sex, with Lesion Skin or Seborrheic Keratosis. Patients with the condition only — healthy volunteers not accepted.
Results — posted to ClinicalTrials.gov
Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.
Clearance of SK LesionsPrimary· 106-day post-treatment
Total Number of treated SK lesions per participant rated as clear or mostly-clear by the Principal Investigator at each clinical site.
Group
Value
95% CI
Nano-Pulse Stimulation (NPS) Lesion
82
Adverse events — posted to ClinicalTrials.gov
Time frame: 3.5 months (106 days).
Reporting threshold: 0%.
Adverse-event reports describe events observed during the trial — not all are caused by the drug.
The primary purpose of this trial is to evaluate Nano-Pulse Stimulation (NPS) to clear or remove Seborrheic Keratosis (SK) lesions from off-facial areas of healthy adult subjects.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Pulse Biosciences, Inc.
Last refreshed: 22 August 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03846531.